An observational study in Identify Existing Gaps and Code Blue Systems Organization and Implementation Remain Heterogeneous, and no National Data Are Available on Their Current Status, sponsored by National Hepatology & Tropical Medicine Research Institute. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by National Hepatology & Tropical Medicine Research Institute · Observational
In Egypt, Code Blue systems have been introduced in many healthcare institutions; however, their organization and implementation remain heterogeneous, and no national data are available regarding their current status, operational characteristics, quality monitoring, or implementation barriers. A comprehensive national assessment is therefore needed to identify existing gaps, benchmark current practices against international recommendations, and guide future quality improvement initiatives.
This study is a national multicenter cross-sectional survey designed to evaluate the current implementation, organization, resources, and perceived effectiveness of Code Blue systems in Egyptian hospitals.
An electronic questionnaire will be distributed nationwide through professional medical societies, hospital administrations, intensive care networks, emergency medicine societies, nursing associations, and professional social media platforms.
Questionnaire items include multiple-choice questions, dichotomous (Yes/No) responses, Likert-scale ratings, and open-ended questions. The estimated completion time is approximately 7-10minutes.
To ensure equitable contribution from participating hospitals and to minimize potential clustering or overrepresentation of responses from hospitals with larger numbers of healthcare personnel, the number of eligible respondents contributing to the survey from each hospital will be limited to a maximum of 10 participants per hospital. Eligible participants will be selected from healthcare professionals directly involved in or familiar with the Code Blue system, including physicians and nursing staff. This approach will ensure that no single hospital disproportionately influences the overall findings while allowing representation of different professional perspectives within each institution. If more than 10 eligible healthcare professionals from the same hospital are willing to participate, recruitment will be capped at 10 respondents.
National Hepatology & Tropical Medicine Research Institute is the lead sponsor of 20 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The target population consists of healthcare professionals aged >18 years old directly involved in the organization, management, supervision, or operation of Code Blue systems within their institutions.
Eligible respondents include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthcare professionals who:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Perceived effectiveness
Perceived overall effectiveness of the Code Blue system
Time frame: immediately after the survey completion
Availability and organizational characteristics of Code Blue systems
by asking about the presence and duration of the implementation of the code blue system in the hospital
Time frame: immediately after the survey completion
Code Blue team structure and readiness
by asking about the 24/7 availability of trained, competent team
Time frame: immediately at the time of the survey
Training and preparedness of Code Blue personnel
By asking about mandatory BLS/ALS training
Time frame: immediately after the survey completion
Documentation, auditing
by asking about the documentation of Code Blue events and recording of response time, survival to discharge, and neurological outcomes, as well as post-event debriefing and regular case auditing.
Time frame: immediately at the time of the survey
Monitoring of quality indicators
by asking about response time, time to first defibrillation, CPR quality, ROSC, survival to discharge, and neurological outcomes.
Time frame: immediately at the time of the survey
Barriers against effective implementation
By asking about the presence of staffing, training, communication, delayed response, equipment availability, hospital support, funding, workload, and the presence of written policies.
Time frame: immediately after the survey completion
Healthcare professionals' recommendations for strengthening
by asking about the best choice (one/or more); national guidelines, mandatory BLS/ALS certification, a national Code Blue registry, digital reporting, mandatory mock codes, and national accreditation standards.
Time frame: immediately after the survey completion
Plan to share: Undecided — Individual participant data (IPD) will not be made publicly available because the dataset contains potentially identifiable information related to participating healthcare professionals and hospitals. De-identified data may be made available from the corresponding author upon reasonable request, subject to ethical and institutional approval and applicable data-protection requirements.
Ran from Sep 2026 to primary completion in Sep 2026, 0 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Hepatology & Tropical Medicine Research Institute